Skip to main content
Top
Literature
1.
go back to reference Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–60.CrossRefPubMed Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–60.CrossRefPubMed
2.
go back to reference Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.CrossRefPubMed Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.CrossRefPubMed
Metadata
Title
Agranulocytosis due to an α-glucosidase inhibitor, voglibose
Authors
Reo Yoshikawa
Ruka Hishinuma
Hiroshi Kaneko
Hidekatsu Yanai
Publication date
01-09-2015
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2015
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-014-0242-7

Other articles of this Issue 3/2015

International Journal of Diabetes in Developing Countries 3/2015 Go to the issue